» Articles » PMID: 8239149

Endothelin-1 in Adult Respiratory Distress Syndrome

Overview
Specialty Pulmonary Medicine
Date 1993 Nov 1
PMID 8239149
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Endothelin-1 (ET-1), a potent vasoconstrictor peptide produced by endothelial cells and degraded predominantly in the pulmonary vasculature, has been implicated in the development of various organ dysfunctions. To determine the pathophysiologic role of ET-1 in adult respiratory distress syndrome (ARDS) and the impact of impaired lung function on transpulmonary peptide handling, we compared plasma levels and pulmonary ET-1 balance in 14 patients with ARDS and in seven healthy control subjects. To obtain comparable conditions in both groups, the ET-1 level was raised in the control group by exogenous infusion (0.4 pmol/kg/min) to 9.4 +/- 0.8 pmol/L. ARDS was accompanied by a hyperdynamic circulatory pattern with increased cardiac output and depressed total vascular resistance but, simultaneously, pulmonary hypertension. Venous ET-1 concentration was massively increased in ARDS (9.8 +/- 1.2 versus 2.1 +/- 0.2 pmol/L, p < 0.001). In control subjects, the lung cleared the major fraction of ET-1 (fractional extraction 43 +/- 8.8%, uptake 12.5 +/- 2.5 pmol/min). In contrast, in ARDS there was a pronounced pulmonary releases into the circulation (32.8 +/- 10.3 pmol/min). We conclude that ET-1 concentrations are elevated in ARDS as the result of both increased formation and decreased disposal. Lung failure affects not only gas exchange but also nonrespiratory, metabolic pulmonary functions.

Citing Articles

Transpulmonary Plasma Endothelin-1 Arterial:Venous Ratio Differentiates Survivors from Non-Survivors in Critically Ill Patients with COVID-19-Induced Acute Respiratory Distress Syndrome.

Vassiliou A, Roumpaki A, Keskinidou C, Athanasiou N, Tsipilis S, Jahaj E Int J Mol Sci. 2024; 25(19).

PMID: 39408968 PMC: 11476705. DOI: 10.3390/ijms251910640.


The Association of Endothelin-1 with Early and Long-Term Mortality in COVID-19.

Turgunova L, Mekhantseva I, Laryushina Y, Alina A, Bacheva I, Zhumadilova Z J Pers Med. 2023; 13(11).

PMID: 38003873 PMC: 10672100. DOI: 10.3390/jpm13111558.


A targetable 'rogue' neutrophil-subset, [CD11b+DEspR+] immunotype, is associated with severity and mortality in acute respiratory distress syndrome (ARDS) and COVID-19-ARDS.

Herrera V, Walkey A, Nguyen M, Gromisch C, Mosaddhegi J, Gromisch M Sci Rep. 2022; 12(1):5583.

PMID: 35379853 PMC: 8977568. DOI: 10.1038/s41598-022-09343-1.


Pulmonary artery targeted therapy in treatment of COVID-19 related ARDS. Literature review.

Puk O, Nowacka A, Smulewicz K, Mocna K, Bursiewicz W, Kesy N Biomed Pharmacother. 2022; 146:112592.

PMID: 35062063 PMC: 8709827. DOI: 10.1016/j.biopha.2021.112592.


Increased Neutrophil-Subset Associated With Severity/Mortality In ARDS And COVID19-ARDS Expresses The Dual Endothelin-1/VEGFsignal-Peptide Receptor (DEspR): An Actionable Therapeutic Target.

Herrera V, Walkey A, Nguyen M, Gromisch C, Mosaddhegi J, Gromisch M Res Sq. 2021; .

PMID: 34545358 PMC: 8452107. DOI: 10.21203/rs.3.rs-846250/v1.